Registration Successful...
null you have successfully logged registered and logged in
MEET FLUMIST HOME

Flu protection. Delivered.

Flu protection. Delivered.

Approved for self-administration1

Here's what you should know:

FluMist Proven Vaccine

The same proven FluMist vaccine1

FluMist New Way

A new, convenient option for eligible patients (2-49) and caregivers to self-administer1*

A caregiver should administer FLUMIST to individuals ages 2-17

FluMist Available in Pharmacy

Will also remain available
in office and in pharmacy for administration by an HCP

Get the latest updates

Learn how FluMist Home can help give patients and caregivers another option for flu protection

Anticipated FLU Season
How will it work?
Order FluMist Online

Patients order online

FluMist Pharmacist Review

A Pharmacist reviews the information and provides approval for appropriate patients

FluMist Insured Patients

Insured patients pay a small shipping fee† to get FluMist Home delivered on their selected date

FluMist Administer At Home

Patients and caregivers administer at home

FluMist Patient Support

Support for you and your patients every step of the way

*Local restrictions may apply.

†Per household order.

Together we can help protect patients against the flu

FluMist Home is here to help as many people get vaccinated as possible. Patients will have another option to get flu protection. FluMist Home will be especially helpful for patients who are unable to make it to a doctor’s office or pharmacy to receive their annual influenza vaccination.

A self-administration study demonstrated that people were able to self-administer FluMist to themselves and others successfully.2‡

‡People in the study had varying educational levels.

Get the latest updates

Please fill out the form below to get the latest updates on FluMist Home and resources to support your office.

The processing of this request requires the use of cookies and website tracking technologies that are available on this website. By clicking Submit, I agree to the storage of these cookies and website tracking technologies on my device. See our Privacy Policy for more information.

AstraZeneca is committed to helping healthcare professionals provide appropriate care to their patients. Please provide us with the following information so that we can keep your records up to date and can send you any information that you request. If in the future you no longer want to receive health-related materials from AstraZeneca, please call 1-800-236-9933. Please visit www.azprivacynotice.com to review our Privacy Notice.

IMPORTANT SAFETY INFORMATION

  • Do not administer FLUMIST to persons who have had a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine, including egg protein, or after a previous dose of any influenza vaccine, or to children and adolescents through 17 years of age who are receiving aspirin or aspirin-containing therapy
  • In clinical trials, the risks of hospitalization and wheezing were increased in children younger than 2 years of age who received FLUMIST
  • Children younger than 5 years of age with recurrent wheezing and persons of any age with asthma may be at increased risk of wheezing following the administration of FLUMIST. FLUMIST has not been studied in persons with severe asthma or active wheezing
  • If Guillain-Barré syndrome has occurred within 6 weeks of any prior influenza vaccination, the decision to give FLUMIST should be based on careful consideration of the potential benefits and risks
  • The effectiveness of FLUMIST has not been studied in immunocompromised persons
  • The safety of FLUMIST in individuals with underlying medical conditions that may predispose them to complications following wild-type influenza infection has not been established
  • Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of FLUMIST
  • FLUMIST may not protect all individuals receiving the vaccine
  • The most common solicited adverse reactions (≥10% in vaccine recipients and at least 5% greater than in placebo) reported after FLUMIST were runny nose or nasal congestion (ages 2-49 years), fever >100 °F (children ages 2-6 years), and sore throat (adult ages 18-49 years)

FLUMIST is a vaccine indicated for active immunization of persons 2 through 49 years of age for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. FLUMIST is for intranasal administration only.

Please see full Prescribing Information for FLUMIST, including Patient Information.

You may report side effects related to AstraZeneca products.